discovered that evodiamine, by downregulating MUC1-C protein expression, modulates PD-L1 expression, thereby effectively inhibiting tumor growth and inducing apoptosis, while enhancing CD8+ T cells’ effector function, with its combination with anti-PD-1 monoclonal antibodies significantly bolstering tumor control (105). The gene discussed is CD8A; the disease is neoplasm.